Compare BIT & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIT | ORGO |
|---|---|---|
| Founded | 2013 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.9M | 624.4M |
| IPO Year | N/A | N/A |
| Metric | BIT | ORGO |
|---|---|---|
| Price | $13.24 | $5.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 92.4K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 9.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $465,218,000.00 |
| Revenue This Year | N/A | $8.14 |
| Revenue Next Year | N/A | $6.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.24 |
| 52 Week Low | $13.65 | $2.61 |
| 52 Week High | $15.97 | $7.08 |
| Indicator | BIT | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 55.40 | 65.12 |
| Support Level | $13.10 | $4.66 |
| Resistance Level | $13.22 | $5.83 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 72.71 | 92.02 |
BlackRock Multi-Sector Income Trust is a closed-end investment management company. It invests on behalf of its clients. The fund's primary investment objective is to provide a high level of current income, with a secondary objective of capital appreciation. The company seeks to achieve its investment objectives by investing, under normal market conditions, a majority of its assets in loan and debt instruments and other investments with similar economic characteristics. Its portfolio consists of Corporate Bonds, Asset-Backed Securities, Preferred Securities, and others.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.